CAR-T Deal Review
In 2012, the striking clinical success of CAR-T therapy in treating acute lymphoblastic leukemia (ALL) in the case of Emily Whitehead was a real game changer for the industry. Since then, there has been an explosion of commercial activity.
In this CAR-T Deal Review we have captured the number and diversity of deals done in this space over the past four years. Included are strategic partnerships, acquisition and licensing deals done between CAR-T companies, Big Pharma, smaller organizations, and academic institutions from 2012 through August 2016. These deals cover intellectual property, new approaches for creating CARs using gene-editing technologies, expansion to allogeneic approaches, manufacturing, combination therapies, and more.